Skip to main
INAB
INAB logo

IN8BIO (INAB) Stock Forecast & Price Target

IN8BIO (INAB) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IN8bio Inc. demonstrates a positive financial outlook due to its promising clinical advancements, particularly with the INB-100 candidate, which exhibits significant efficacy in preventing relapse in high-risk acute myeloid leukemia (AML) patients following haploidentical stem cell transplantation. The reported 100% overall survival rate at one year for patients treated with INB-100, compared to the historical average of approximately 70%, underscores the potential impact of this treatment on patient outcomes and market penetration. Additionally, the absence of serious treatment-related adverse events enhances the profile of INB-100, suggesting a favorable risk-benefit ratio that could drive future commercial success as the multi-center expansion study progresses toward completion in 2025.

Bears say

The financial outlook for IN8bio Inc appears negative, primarily due to a recent downward revision of the 12-month price target from $8.00 to $6.00, indicating reduced confidence in the company's future stock performance. Although preclinical studies for INB-619 demonstrate potential therapeutic benefits, there remains uncertainty surrounding the transition from preclinical to clinical stages and the ability to successfully commercialize their product candidates. The reliance on several experimental therapies, coupled with the inherent risks of clinical-stage development, heightens the financial risk associated with investing in IN8bio.

IN8BIO (INAB) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IN8BIO (INAB) Forecast

Analysts have given IN8BIO (INAB) a Strong Buy based on their latest research and market trends.

According to 7 analysts, IN8BIO (INAB) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IN8BIO (INAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.